InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.85
(
1.06%
)
Bitcoin
70,158.39
(
2.41%
)
Post# of 251943
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Summer2762

Send PM Follow Ignore
Followers 7
Posts 193
Boards Moderated 0
Alias Born 10/26/2011

Summer2762

Re: biomaven0 post# 168644

Tuesday, 10/22/2013 7:02:10 PM

Tuesday, October 22, 2013 7:02:10 PM

Post# of 251943
Re: MDVN rPFS

Xtandi HR an amazing 0.19
Zytiga HR 0.425



That also caught my attention. However, the difference might be due to the fact that the control arm in PREVAIL was placebo. It was prednisone in the Zytiga trial.

A supporting fact for the above argument is that rPFS of the control arms were 8.28m vs 3.9m in in the Zytiga trial vs this trial. I cannot think of any other reason why the median rPFS should differ this much in these trials.

Another (weaker) supporting argument is that I can guesstimate that the median rPFS of Zytiga from the KM graph to be about 16.5m. This should be about in the same ballpark for Enzalutamide (based on the lower CI, which was 13.8m).

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up